Based on this, we validated that PD-L1 negatively regulated NLRP3 in GC cells in our preliminary work, which rendered the possibility that targeting PD-L1-NLRP3 pathway was novel to enhance cisplatin-sensitivity in GC cells. This evidence concerns the gene NLRP3 and gastric cancer.